The introduction of the PDE4 inhibitor, roflumilast for moderate to severe COPD, whilst of benefit, has not provided a change in direction for the treatment of this disease, limited in part by bothersome gastrointestinal side effects (9, 10). This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.